China Updates Narcotics and Psychotropic Substances Catalog, Adds Three Substances
The National Medical Products Administration (NMPA), Ministry of Public Security, and National Health Commission have...
Fineline Cube
Sinovac Biotech Advances SA55 COVID-19 Neutralizing Antibody into Phase II Trials
China-based vaccines firm Sinovac Biotech Ltd (NASDAQ: SVA) has announced the completion of a Phase...
Shanghai Haoyuan Chemexpress Aims to Raise RMB 1.16 Billion with Convertible Bonds
China-based Contract Development and Manufacturing Organization (CDMO) Shanghai Haoyuan Chemexpress Co., Ltd (SHA： 688131) has...
Jiangsu Hengrui Pharmaceuticals Gets NMPA Approval for HRS-7450 Acute Ischemic Stroke Study
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...
SinoMab BioScience Receives NMPA Approval for Phase I Study of Atopic Dermatitis Drug SM17
Hong Kong-based biotechnology company SinoMab BioScience Ltd (HKG: 3681) has received approval from the National...
Merck & Co. Becomes First Multinational to Register Unit in Hainan’s Lecheng Pilot Zone
US pharmaceutical major Merck, Sharp & Dohme Inc., (MSD, NYSE: MRK) has officially registered a...
Haisco Pharmaceutical Gets NMPA Approval for HSK21542 Chronic Pruritus Clinical Study
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that it has received approval...
ImmuneOnco’s IMM2510 and IMM27M Achieve Milestones in Phase I Clinical Trials
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced the completion of patient enrollment for...
CDE Indicates BTD Status for Visirna’s VSA001, Sperogenix’s Vamorolone, and Zai Lab’s Efgartigimod
The Center for Drug Evaluation (CDE) website has indicated that Visirna Therapeutics’ novel siRNA therapy...
Shanghai Junshi Biosciences to Acquire Stake in Anlingke Biopharmaceutical for Cancer Therapy Programs
China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced its intention to...
Broncus Medical Inc. to Acquire Fibernova Holding Corporation for USD 2.7 Million
Broncus Medical Inc., (HKG: 2216) a provider of lung disease precision intervention solutions with operations...
Lepu Medical Technology Receives NMPA Approval for MemoSorb Biodegradable PFO Occluder
China-based cardiovascular disease solutions provider Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003) has announced...
EA Pharma and TransThera Sciences Collaborate on GI and Liver Disease Therapies
Japan-based EA Pharma Co., Ltd and China-headquartered TransThera Sciences (Nanjing) Inc. have jointly announced the...
GRIT Biotechnology Secures RMB 400 Million in Series B Financing to Advance TIL Pipeline
China-based GRIT Biotechnology has announced the completion of a Series B financing round, raising RMB...
Oriomics Secures Series B+ Funding to Advance Liver and Digestive Cancer Screening
Hangzhou-based Oriomics, a specialist in cancer screening based on circulating tumor DNA (ctDNA) methylation detection,...
Sichuan Kelun Pharmaceutical Submits Biosimilar Cetuximab for NMPA Approval
Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422), through its innovative drug development subsidiary Sichuan Kelun-Biotech...
Biotyx Medical Secures Over RMB 200 Million in Series B Financing for Iron-Based Stents
China-based Biotyx Medical (Shenzhen) Co.,Ltd, known as the world’s only developer of iron-based absorbable stents,...
United Laboratories’ UBT251 Receives Tacit Approval for NAFLD Clinical Study in China
Hong Kong firm United Laboratories International Holdings Ltd (HKG: 3933) has announced that its Category...
Abbisko Therapeutics Receives EMA Approval for Phase III Study of Pimicotinib for TGCT
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received approval...
AriBio Files for Phase III Clinical Trial Approval in China for Alzheimer’s Drug AR1001
South Korean clinical-stage biotech AriBio Co. has announced the filing for Phase III clinical trial...